WeChat Quit Coach Pilot Study

Sponsor
NYU Langone Health (Other)
Overall Status
Recruiting
CT.gov ID
NCT05130788
Collaborator
Asian Americans for Equality (Other), Chinese American Planning Council (Other)
50
1
2
6.6
7.5

Study Details

Study Description

Brief Summary

The study team will develop and assess the feasibility and acceptability of a social media-based text messaging smoking cessation intervention targeting Chinese immigrant smokers in New York City (NYC). For Aim 1, the study team will develop a message library for the WeChat Quit Coach smoking cessation program and conduct in-depth interviews with 20 Chinese immigrant smokers in person to assess content relevance. For Aim 2, a two-arm, open-labeled, pilot randomized controlled trial (RCT) will be conducted to test the feasibility and acceptability of the WeChat Quit Coach intervention among 50 Chinese immigrant smokers. Participants will be randomized to intervention (n=25) or control group (n=25). Participants in the intervention group will receive a 6-week WeChat Quit Coach intervention through WeChat private group. Participants in the control group will receive a leaflet with information about existing smoking cessation programs that focus on Chinese American smokers. All the 50 participants will be offered a 4-week supple of nicotine replacement therapy (NRT) patches and lozenge. Participants will complete a baseline in-person survey at enrollment, a 6-week follow-up phone survey immediately after the intervention, and a 6-month follow-up phone survey. Biochemical test (exhaled carbon monoxide test) will be conducted to confirm abstinence among those who report no smoking in past 7-day at 6-week and 6-month follow-up surveys. Post-test in-depth interviews will be conducted with 15 participants in person from the intervention group at 6-week follow-up to obtain more information about the usability and perceptions about the WeChat Quit Coach program.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: WeChat Quit Coach
  • Behavioral: Leaflet
  • Drug: Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Feasibility and Acceptability of a WeChat Quit Coach Smoking Cessation Intervention: A Pilot, Open-labeled, Randomized Controlled Trial Among Chinese Immigrant Smokers
Actual Study Start Date :
Jan 10, 2022
Anticipated Primary Completion Date :
Jul 31, 2022
Anticipated Study Completion Date :
Jul 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

Behavioral: WeChat Quit Coach
WeChat Quit Coach intervention will be delivered via WeChat private groups for 6 weeks (<1 minute per day). During the intervention period, participants will receive a text message at a fixed point of time every day (e.g., 8:00 am). The messages are designed to build motivations and skillset to quit smoking. Participants will also receive a daily group discussion question (e.g., "If you are to give one piece of advice to someone who has not made the decision to quit smoking, what would you say to his/her?"), and be encouraged to respond to the question. Participants can comment on group members' responses and ask questions related to smoking and quitting either in group (so everyone in the group can see the message) or directly to the coach (so only the coach can see the message). The coach will respond to the questions within 24 hours. The PI and the RA will moderate group discussions.

Drug: Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges
Participants in both groups will be offered a 4-week supply of NRT patches and lozenge but not forced to use the medications. The medications are free to participants. If participants want to try or use the medications, the study team will mail the patches and lozenge (with a Chinese version of the instruction) or deliver in person.
Other Names:
  • Habitrol
  • Nicorette
  • Active Comparator: Control Group

    Behavioral: Leaflet
    Participants in the control group will receive a leaflet with information about existing smoking cessation programs targeting Chinese American smokers.

    Drug: Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges
    Participants in both groups will be offered a 4-week supply of NRT patches and lozenge but not forced to use the medications. The medications are free to participants. If participants want to try or use the medications, the study team will mail the patches and lozenge (with a Chinese version of the instruction) or deliver in person.
    Other Names:
  • Habitrol
  • Nicorette
  • Outcome Measures

    Primary Outcome Measures

    1. Participant Satisfaction with Smoking Cessation Coach [Week 6 Follow-Up]

      A 5-point Likert scale will be used to report satisfaction. The total range in score is 1-5; the higher the score, the higher the satisfaction.

    2. Participant Satisfaction with Overall WeChat Program [Week 6 Follow-Up]

      A 5-point Likert scale will be used to report satisfaction. The total range in score is 1-5; the higher the score, the higher the satisfaction.

    Secondary Outcome Measures

    1. Number of Quit Attempts [Week 6 Follow-Up]

    2. Number of Quit Attempts [Month 6 Follow-Up]

    3. Number of Participants Who Reported Reductions in Their Cigarette Consumption [Week 6 Follow-Up]

    4. Number of Participants Who Reported Reductions in Their Cigarette Consumption [Month 6 Follow-Up]

    5. Number of Participants Who Reported a 7-Day Point Prevalence Abstinence [Week 6 Follow-Up]

    6. Number of Participants Who Reported a 7-Day Point Prevalence Abstinence [Month 6 Follow-Up]

    7. Number of Participants Who were biochemically confirmed to have quit smoking [Week 6 Follow-Up]

    8. Number of Participants Who were biochemically confirmed to have quit smoking [Month 6 Follow-Up]

    9. Number of Participants Who reported increased knowledge about smoking [Week 6 Follow-Up]

    10. Number of Participants Who reported increased knowledge about smoking [Month 6 Follow-Up]

    11. Number of Participants Who reported a change in self-efficacy for quitting smoking [Week 6 Follow-Up]

    12. Number of Participants Who reported a change in self-efficacy for quitting smoking [Month 6 Follow-Up]

    13. Number of Participants Who reported a change in the readiness for quitting smoking [Week 6 Follow-Up]

    14. Number of Participants Who reported a change in the readiness for quitting smoking [Month 6 Follow-Up]

    15. Number of Participants Who reported using NRT during the intervention period [Week 6 Follow-Up]

    16. Number of Participants Who reported using NRT during the intervention period [Month 6 Follow-Up]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age 18-65 years

    2. Chinese immigrant

    3. Have smoked at least 100 cigarettes in a lifetime

    4. Smoke ≥3 days per week

    5. Be somewhat interested in quitting smoking

    6. Has a Smartphone

    7. Current WeChat user who uses WeChat on ≥3 days per week

    8. Live in NYC

    9. Can read and speak Chinese

    10. Be able to provide consent

    Exclusion Criteria:
    1. Current participation in other smoking cessation treatment program(s)

    2. Be pregnant or breastfeeding

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NYU Langone Health New York New York United States 10016

    Sponsors and Collaborators

    • NYU Langone Health
    • Asian Americans for Equality
    • Chinese American Planning Council

    Investigators

    • Principal Investigator: Nan Jiang, PhD, NYU Langone Health

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    NYU Langone Health
    ClinicalTrials.gov Identifier:
    NCT05130788
    Other Study ID Numbers:
    • 20-01959
    First Posted:
    Nov 23, 2021
    Last Update Posted:
    Jan 31, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 31, 2022